CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Oncotarget · 2018 · PMC5849188 · PMID 29560124

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Quantification of the area under the curve (AUC) revealed that the difference in tumor growth between VSV-CD30 and mock treated was highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.